Evidence map›Paper›PMID 25071320›Full record

ReviewWorld journal of gastroenterology2014

Epidemiology and natural history of hepatitis C virus infection.

Mei-Hsuan Lee, Hwai-I Yang, Yong Yuan, Gilbert L'Italien, Chien-Jen Chen

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 5 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 5 syntheses or guidelines pooled it, 190 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Role of Intestinal Microbes in Chronic Liver Diseases.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mei-Hsuan LeeMei-Hsuan Lee, the Institute of Clinical Medicine, National Yang-Ming University, Taipei 155, Taiwan.
Hwai-I YangMei-Hsuan Lee, the Institute of Clinical Medicine, National Yang-Ming University, Taipei 155, Taiwan.
Yong YuanMei-Hsuan Lee, the Institute of Clinical Medicine, National Yang-Ming University, Taipei 155, Taiwan.
Gilbert L'ItalienMei-Hsuan Lee, the Institute of Clinical Medicine, National Yang-Ming University, Taipei 155, Taiwan.
Chien-Jen ChenMei-Hsuan Lee, the Institute of Clinical Medicine, National Yang-Ming University, Taipei 155, Taiwan.
National Yang Ming Chiao Tung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) affects 130-210 million people worldwide and is one of the major risk factors for hepatocellular carcinoma. Globally, at least one third of hepatocellular carcinoma cases are attributed to HCV infection, and 350000 people died from HCV related diseases per year. There is a great geographical variation of HCV infection globally, with risk factors for the HCV infection differing in various countries. The progression of chronic hepatitis C to end-stage liver disease also varies in different study populations. A long-term follow-up cohort enrolling participants with asymptomatic HCV infection is essential for elucidating the natural history of HCV-caused hepatocellular carcinoma, and for exploring potential seromarkers that have high predictability for risk of hepatocellular carcinoma. However, prospective cohorts comprising individuals with HCV infection are still uncommon. The risk evaluation of viral load elevation and associated liver disease/cancer in HCV (REVEAL-HCV) study has followed a cohort of 1095 residents seropositive for antibodies against hepatitis C virus living in seven townships in Taiwan for more than fifteen years. Most of them have acquired HCV infection through iatrogenic transmission routes. As the participants in the REVEAL-HCV study rarely receive antiviral therapies, it provides a unique opportunity to study the natural history of chronic HCV infection. In this review, the prevalence, risk factors and natural history of HCV infection are comprehensively reviewed. The study cohort, data collection, and findings on liver disease progression of the REVEAL-HCV study are described.

Indexed as

AdultAgedAged, 80 and overAge FactorsCarcinoma, HepatocellularDisease ProgressionFemaleHepacivirusHepatitis CHumansIncidenceLiver CirrhosisLiver NeoplasmsMaleMiddle AgedPrevalenceEpidemiologyHepatitis C virusLong-term liver progressionRisk evaluation of viral load elevation and associated liver disease/cancer

Identifiers

PMID25071320
PMCPMC4110557
OpenAlexW2362391013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.